Literature DB >> 6439955

The costs and effects of behavioral programs in chronic obstructive pulmonary disease.

C D Toevs, R M Kaplan, C J Atkins.   

Abstract

This paper uses a General Health Policy Model to determine the cost-effectiveness of an experimental behavioral program for patients with chronic obstructive pulmonary disease (COPD). Patients were randomly assigned to either experimental or control groups, and only those in the experimental groups were given the behavioral strategies. Health status information was collected over 18 months, and the Health Policy Model translated program outcomes into well-year equivalents. At the end of the program, greater improvements in health status were observed in the experimental subjects, and a total of 4.41 well-years were produced. Costs of the program were gathered on a per-year basis using an administrative perspective. Both costs and health effects were discounted to present value using a 5% discount rate. Dividing costs by effects, the COPD program produced well-years at a unit cost of $24,256. Comparing the cost-utility figure to those of other health care programs using the General Health Policy Model, the behavioral program appears reasonably cost-effective as an adjunct therapy for patients suffering from COPD.

Entities:  

Mesh:

Year:  1984        PMID: 6439955     DOI: 10.1097/00005650-198412000-00004

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  9 in total

1.  The reliability of cost-utility estimates in cost-per-QALY league tables .

Authors:  S Petrou; M Malek; P G Davey
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

2.  Rehabilitation for people with chronic lung disease.

Authors:  M D Morgan; F H Quirk; S J Singh
Journal:  Qual Health Care       Date:  1995-12

Review 3.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

Review 4.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.

Authors:  M P Rutten-van Mölken; E K Van Doorslaer; M C Jansen; E E Van Essen-Zandvliet; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

6.  A general health policy model: update and applications.

Authors:  R M Kaplan; J P Anderson
Journal:  Health Serv Res       Date:  1988-06       Impact factor: 3.402

Review 7.  Cost effectiveness of biofeedback and behavioral medicine treatments: a review of the literature.

Authors:  C J Schneider
Journal:  Biofeedback Self Regul       Date:  1987-06

Review 8.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 9.  Optimizing economic outcomes in the management of COPD.

Authors:  Roberto Dal Negro
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.